Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant TACE + lenvatinib + camrelizumab versus upfront hepatectomy for resectable hepatocellular carcinoma with portal vein tumor thrombus
ChiCTR2300069972Phase 2Not yet recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenvatinib and camrelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Fujian Provincial Hospital. Primary endpoints: Overall survival rate and Recurrence-free survival rate. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
lenvatinibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300069972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069972.